His scientific interests lie mostly in Pathology, Ovarian cancer, Serous fluid, Tissue microarray and Cancer research. C. Blake Gilks is involved in the study of Pathology that focuses on Immunohistochemistry in particular. His study in Ovarian cancer is interdisciplinary in nature, drawing from both Disease, Oncology and Tumor-infiltrating lymphocytes.
His Serous fluid research integrates issues from Serous carcinoma, Carcinoma, Clear cell, Ovarian carcinoma and Microsatellite instability. He has included themes like Immunostaining, Molecular biology, Breast carcinoma, Estrogen receptor and Hierarchical clustering in his Tissue microarray study. His Cancer research research includes elements of Carcinogenesis, Tumor progression and Immunology, Immune system.
His primary areas of investigation include Pathology, Serous fluid, Internal medicine, Immunohistochemistry and Carcinoma. His research in Pathology intersects with topics in Cancer, Serous carcinoma and Ovary. In his study, Cancer research and Chemotherapy is inextricably linked to Ovarian cancer, which falls within the broad field of Serous fluid.
In his research on the topic of Cancer research, ARID1A is strongly related with KRAS. His work deals with themes such as Endocrinology and Oncology, which intersect with Internal medicine. His Carcinoma study incorporates themes from Biopsy, Radiology, Stage, Endometrial cancer and Adenocarcinoma.
C. Blake Gilks mostly deals with Pathology, Carcinoma, Immunohistochemistry, Ovarian cancer and Internal medicine. His Pathology study combines topics in areas such as Cancer, Serous carcinoma and Convolutional neural network. His Carcinoma research is multidisciplinary, incorporating elements of Serous fluid, Biopsy, Endometrial cancer and Molecular classification.
The study incorporates disciplines such as Vulvar Squamous Cell Carcinoma, Cancer research and DNA mismatch repair in addition to Immunohistochemistry. His Ovarian cancer research includes themes of Disease and Chemotherapy. His Tissue microarray research incorporates elements of Clear cell and Ovary.
C. Blake Gilks mainly focuses on Carcinoma, Pathology, Endometrial cancer, Immunohistochemistry and Cancer research. His research integrates issues of Ovarian carcinoma, Biopsy and DNA mismatch repair in his study of Carcinoma. Pathology and Serous carcinoma are commonly linked in his work.
The concepts of his Endometrial cancer study are interwoven with issues in Hysterectomy, Oncology and Clear cell carcinoma. His Cancer research research is multidisciplinary, relying on both Phenotype, Cell, Germline mutation and Cellular differentiation. His work focuses on many connections between Serous fluid and other disciplines, such as Concordance, that overlap with his field of interest in Biomarker.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
Torsten O. Nielsen;Forrest D. Hsu;Kristin Jensen;Maggie Cheang.
Clinical Cancer Research (2004)
Integrated genomic characterization of endometrial carcinoma
Gad Getz;Stacey B. Gabriel;Kristian Cibulskis;Eric Lander.
Nature (2013)
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T reg cells
Andrea Facciabene;Xiaohui Peng;Ian S. Hagemann;Klara Balint.
Nature (2011)
Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies
Martin Köbel;Martin Köbel;Steve E Kalloger;Niki Boyd;Steven McKinney.
PLOS Medicine (2008)
Mutation of FOXL2 in Granulosa-Cell Tumors of the Ovary
Sohrab P Shah;Martin Köbel;Janine Senz;Ryan D Morin.
The New England Journal of Medicine (2009)
A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells.
Robert B. West;Brian P. Rubin;Melinda A. Miller;Subbaya Subramanian.
Proceedings of the National Academy of Sciences of the United States of America (2006)
Cancer-Associated Mutations in Endometriosis without Cancer
Michael S. Anglesio;Nickolas Papadopoulos;Ayse Ayhan;Tayyebeh M. Nazeran.
The New England Journal of Medicine (2017)
Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancer
Aline Talhouk;Melissa K. McConechy;Samuel Leung;Winnie Yang.
Cancer (2017)
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study
Weiva Sieh;Martin Köbel;Teri A Longacre;David D Bowtell;David D Bowtell.
Lancet Oncology (2013)
Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors
Katy Milne;Martin Köbel;Steven E. Kalloger;Rebecca O. Barnes.
PLOS ONE (2009)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of British Columbia
University of British Columbia
Memorial Sloan Kettering Cancer Center
Stanford University
Memorial Sloan Kettering Cancer Center
Harvard University
University of British Columbia
Peter MacCallum Cancer Centre
Peter MacCallum Cancer Centre
University of British Columbia
University of Oxford
MIT
Université Gustave Eiffel
Shandong University of Science and Technology
Korea Advanced Institute of Science and Technology
Texas A&M University at Qatar
Applied Materials (United States)
Chinese Academy of Sciences
Leiden University
Duke University
Queen Mary University of London
University of Arizona
Hokkaido University
Leiden University
Maastricht University
Yonsei University